Find Research outputs

Search results

• Phase i trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies

  Reddy, N., Voorhees, P. M., Houk, B. E., Brega, N., Hinson, J. M. & Jillela, A., Aug 2013, In: Clinical Lymphoma, Myeloma and Leukemia. 13, 4, p. 385-391 7 p.

  Research output: Contribution to journal › Article › peer-review
  26 Scopus citations

• Phase I trial of anti-CD3-stimulated CD4⁺ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer

  Curti, B. D., Ochoa, A. C., Powers, G. C., Kopp, W. C., Alvord, W. G., Janik, J. E., Gause, B. L., Dunn, B., Kopreski, M. S., Fenton, R., Zea, A., Dansky-Ullmann, C., Strobl, S., Harvey, L., Nelson, E., Sznol, M. & Longo, D. L., Aug 1998, In: Journal of Clinical Oncology. 16, 8, p. 2752-2760 9 p.

  Research output: Contribution to journal › Article › peer-review
  49 Scopus citations

• Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer

  Hardy, N. M., Mossoba, M. E., Steinberg, S. M., Fellowes, V., Yan, X. Y., Hakim, F. T., Babb, R. R., Avila, D., Gea-Banacloche, J., Sportés, C., Levine, B. L., June, C. H., Khuu, H. M., Carpenter, A. E., Krumlauf, M. C., Dwyer, A. J., Gress, R. E., Fowler, D. H. & Bishop, M. R., Nov 1 2011, In: Clinical Cancer Research. 17, 21, p. 6878-6887 10 p.

  Research output: Contribution to journal › Article › peer-review
  14 Scopus citations

• Phase i trial of 7-hydroxystaurosporine and fludararbine phosphate: In vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia

  Marti, G. E., Stetler-Stevenson, M., Grant, N. D., White, T., Figg, W. D., Tohnya, T., Jaffe, E. S., Dunleavy, K., Janik, J. E., Steinberg, S. M. & Wilson, W. H., Dec 2011, In: Leukemia and Lymphoma. 52, 12, p. 2284-2292 9 p.

  Research output: Contribution to journal › Article › peer-review
  17 Scopus citations

• Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer

  Gause, B. L., Sznol, M., Kopp, W. C., Janik, J. E., Smith, II. W., Steis, R. G., Urba, W. J., Sharfman, W., Fenton, R. G., Creekmore, S. P., Holmlund, J., Conlon, K. C., VanderMolen, L. A. & Longo, D. L., Jan 1 1996, In: Journal of Clinical Oncology. 14, 8, p. 2234-2241 8 p.

  Research output: Contribution to journal › Article › peer-review
  32 Scopus citations

• Phase i study of S-trans, trans-farnesylthiosalicylic acid (Salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies

  Badar, T., Cortes, J. E., Ravandi, F., O'Brien, S., Verstovsek, S., Garcia-Manero, G., Kantarjian, H. & Borthakur, G., Jul 1 2015, In: Clinical Lymphoma, Myeloma and Leukemia. 15, 7, p. 433-438.e2

  Research output: Contribution to journal › Article › peer-review
  21 Scopus citations

• Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

  Borthakur, G., Kantarjian, H., Ravandi, F., Zhang, W., Konopleva, M., Wright, J. J., Faderl, S., Verstovsek, S., Mathews, S., Andreeff, M. & Cortes, J. E., Jan 2011, In: Haematologica. 96, 1, p. 62-68 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  148 Scopus citations

• Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy

  Sportès, C., Babb, R. R., Krumlauf, M. C., Hakim, F. T., Steinberg, S. M., Chow, C. K., Brown, M. R., Fleisher, T. A., Noel, P., Maric, I., Stetler-Stevenson, M., Engel, J., Buffet, R., Morre, M., Amato, R. J., Pecora, A., Mackall, C. L. & Gress, R. E., Jan 15 2010, In: Clinical Cancer Research. 16, 2, p. 727-735 9 p.

  Research output: Contribution to journal › Article › peer-review
  153 Scopus citations

• Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

  Cortes, J. E., Kantarjian, H., Foran, J. M., Ghirdaladze, D., Zodelava, M., Borthakur, G., Gammon, G., Trone, D., Armstrong, R. C., James, J. & Levis, M., Oct 10 2013, In: Journal of Clinical Oncology. 31, 29, p. 3681-3867 187 p.

  Research output: Contribution to journal › Article › peer-review
  272 Scopus citations

• Phase I study of oral topotecan in hematological malignancies

  Beran, M., O'Brien, S., Thomas, D. A., Tran, H. T., Cortes-Franco, J. E., Giles, F., Estey, E. & Kantarjian, H. M., Nov 1 2003, In: Clinical Cancer Research. 9, 11, p. 4084-4091 8 p.

  Research output: Contribution to journal › Article › peer-review
  12 Scopus citations

• Phase I study of liposomal daunorubicin in patients with acute leukemia

  Cortes, J., O'Brien, S., Estey, E., Giles, F., Keating, M. & Kantarjian, H., 1999, In: Investigational New Drugs. 17, 1, p. 81-87 7 p.

  Research output: Contribution to journal › Article › peer-review
  51 Scopus citations

• Phase I study of Irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia

  Giles, F., Cortes, J., Garcia-Manero, G., Kornblau, S., Estey, E., Kwari, M., Murgo, A. & Kantarjian, H., 2001, In: Investigational New Drugs. 19, 1, p. 13-20 8 p.

  Research output: Contribution to journal › Article › peer-review
  11 Scopus citations

• Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia

  Badar, T., Handisides, D. R., Benito, J. M., Richie, M. A., Borthakur, G., Jabbour, E., Harutyunyan, K., Konoplev, S., Faderl, S., Kroll, S., Andreeff, M., Pearce, T., Kantarjian, H. M., Cortes, J. E., Thomas, D. A. & Konopleva, M., Aug 1 2016, In: American Journal of Hematology. 91, 8, p. 800-805 6 p.

  Research output: Contribution to journal › Article › peer-review
  23 Scopus citations

• Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

  Giles, F., Verstovsek, S., Thomas, D., Gerson, S., Cortes, J., Faderl, S., Ferrajoli, A., Ravandi, F., Kornblau, S., Garcia-Manero, G., Jabbour, E., O'Brien, S., Karsten, V., Cahill, A., Yee, K., Albitar, M., Sznol, M. & Kantarjian, H., Nov 1 2005, In: Clinical Cancer Research. 11, 21, p. 7817-7824 8 p.

  Research output: Contribution to journal › Article › peer-review
  37 Scopus citations

• Phase I study of bortezomib in refractory of relapsed acute leukemias

  Cortes, J., Thomas, D., Koller, C., Giles, F., Estey, E., Faderl, S., Garcia-Manero, G., McConkey, D., Patel, G., Guerciolini, R., Wright, J. & Kantarjian, H., May 15 2004, In: Clinical Cancer Research. 10, 10, p. 3371-3376 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  181 Scopus citations

• Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

  Cortes, J., Faderl, S., Estey, E., Kurzrock, R., Thomas, D., Beran, M., Garcia-Manero, G., Ferrajoli, A., Giles, F., Koller, C., O'Brien, S., Wright, J., Bai, S. A. & Kantarjian, H., Apr 20 2005, In: Journal of Clinical Oncology. 23, 12, p. 2805-2812 8 p.

  Research output: Contribution to journal › Article › peer-review
  47 Scopus citations

• Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome

  Kurzrock, R., Kantarjian, H. M., Blascovich, M. A., Bucher, C., Verstovsek, S., Wright, J. J., Pilat, S. R., Cortes, J. E., Estey, E. H., Giles, F. J., Beran, M. & Sebti, S. M., Jan 15 2008, In: Clinical Cancer Research. 14, 2, p. 509-514 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  19 Scopus citations

• Phase i studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers

  Cortes, J., Tamura, K., Deangelo, D. J., De Bono, J., Lorente, D., Minden, M., Uy, G. L., Kantarjian, H., Chen, L. S., Gandhi, V., Godin, R., Keating, K., McEachern, K., Vishwanathan, K., Pease, J. E. & Dean, E., May 1 2018, In: British Journal of Cancer. 118, 11, p. 1425-1433 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  37 Scopus citations

• Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

  Ghanem, H., Kantarjian, H., Cortes, J., Quintás-Cardama, A. & Jabbour, E., 2013, In: Expert Opinion on Orphan Drugs. 1, 8, p. 607-623 17 p.

  Research output: Contribution to journal › Review article › peer-review

• Phase II trial of web-based tailored asthma management intervention in adolescents at clinics

  Lu, M., Zhang, T., Ownby, D. R., Zoratti, E., Johnson, D. A., William, R., Miree, C. & Joseph, C. L. M., Jul 2019, In: Contemporary Clinical Trials. 82, p. 46-52 7 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

  Garcia-Manero, G., Tambaro, F. P., Bekele, N. B., Yang, H., Ravandi, F., Jabbour, E., Borthakur, G., Kadia, T. M., Konopleva, M. Y., Faderl, S., Cortes, J. E., Brandt, M., Hu, Y., McCue, D., Newsome, W. M., Pierce, S. R., De Lima, M. & Kantarjian, H. M., Jun 20 2012, In: Journal of Clinical Oncology. 30, 18, p. 2204-2210 7 p.

  Research output: Contribution to journal › Article › peer-review
  129 Scopus citations

• Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

  Zakharia, Y., McWilliams, R. R., Rixe, O., Drabick, J., Shaheen, M. F., Grossmann, K. F., Kolhe, R., Pacholczyk, R., Sadek, R., Tennant, L. L., Smith, C. M., Kennedy, E. P., Link, C. J., Vahanian, N. N., Yu, J., Shen, S. S., Brincks, E. L., Rossi, G. R., Munn, D. & Milhem, M., Jun 11 2021, In: Journal for ImmunoTherapy of Cancer. 9, 6, e002057.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  11 Scopus citations

• Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer

  Jazieh, A. R., Komrokji, R., Gupta, A., Patil, S., Flora, D., Knapp, M., Issa, M. & Abdel Karim, N. F. M., Oct 22 2009, In: Cancer Investigation. 27, 9, p. 932-936 5 p.

  Research output: Contribution to journal › Article › peer-review
  11 Scopus citations

• Phase-II trial of tamoxifen in advanced breast cancer

  Wiggans, R. G., Woolley, P. V., Smythe, T., Hoth, D., Macdonald, J. S., Green, L. & Schein, P. S., Aug 1979, In: Cancer Chemotherapy and Pharmacology. 3, 1, p. 45-48 4 p.

  Research output: Contribution to journal › Article › peer-review
  25 Scopus citations

• Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer

  Wiggans, R. G., Woolley, P. V., Macdonald, J. S., Smythe, T., Ueno, W. & Schein, P. S., Feb 1978, In: Cancer. 41, 2, p. 387-391 5 p.

  Research output: Contribution to journal › Article › peer-review
  89 Scopus citations

• Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

  Sanford, D., Kantarjtan, H., Skinner, J., Jabbour, E. & Cortes, J., 2015, In: Haematologica. 100, 12, p. e494-e495

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  16 Scopus citations

• Phase II Trial of Murine Monoclonal Antibody D612 Combined with Recombinant Human Monocyte Colony-stimulating Factor (rhM-CSF) in Patients with Metastatic Gastrointestinal Cancer

  Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Liu, T., Everson, M. P., LoBuglio, A. F., Bucy, R. P., Schlom, J. & Munn, D. H., Oct 1 1995, In: Cancer Research. 55, 19, p. 4339-4346 8 p.

  Research output: Contribution to journal › Article › peer-review
  14 Scopus citations

• Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

  Maiti, A., Naqvi, K., Kadia, T. M., Borthakur, G., Takahashi, K., Bose, P., Daver, N. G., Patel, A., Alvarado, Y., Ohanian, M., DiNardo, C. D., Cortes, J. E., Jabbour, E. J., Garcia-Manero, G., Kantarjian, H. M. & Ravandi, F., Mar 2019, In: Clinical Lymphoma, Myeloma and Leukemia. 19, 3, p. 142-148.e1

  Research output: Contribution to journal › Article › peer-review
  18 Scopus citations

• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

  Lin, N. U., Carey, L. A., Liu, M. C., Younger, J., Come, S. E., Ewend, M., Harris, G. J., Bullitt, E., Van Den Abbeele, A. D., Henson, J. W., Li, X., Gelman, R., Burstein, H. J., Kasparian, E., Kirsch, D. G., Crawford, A., Hochberg, F. & Winer, E. P., 2008, In: Journal of Clinical Oncology. 26, 12, p. 1993-1999 7 p.

  Research output: Contribution to journal › Article › peer-review
  363 Scopus citations

• Phase II trial of interleukin 1α and indomethacin in treatment of metastatic melanoma

  Janik, J. E., Miller, L. L., Longo, D. L., Powers, G. C., Urba, W. J., Kopp, W. C., Gause, B. L., Curti, B. D., Fenton, R. G., Oppenheim, J. J., Conlon, K. C., Holmlund, J. T., Sznol, M., Sharfman, W. H., Steis, R. G., Creekmore, S. P., Alvord, W. G., Beauchamp, A. E. & Smith, J. W., 1996, In: Journal of the National Cancer Institute. 88, 1, p. 44-49 6 p.

  Research output: Contribution to journal › Article › peer-review
  24 Scopus citations

• Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma

  Salman, H., Perez, A., Sparano, J. A., Ratech, H., Negassa, A., Hopkins, U., Villani, G., Fuks, J. & Wiernik, P. H., Aug 1 2003, In: American Journal of Clinical Oncology: Cancer Clinical Trials. 26, 4, p. 338-343 6 p.

  Research output: Contribution to journal › Article › peer-review
  1 Scopus citations

• Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

  Benjamini, O., Dumlao, T. L., Kantarjian, H., O'Brien, S., Garcia-Manero, G., Faderl, S., Jorgensen, J., Luthra, R., Garris, R., Thomas, D., Kebriaei, P., Champlin, R., Jabbour, E., Burger, J., Cortes, J. & Ravandi, F., Mar 2014, In: American Journal of Hematology. 89, 3, p. 282-287 6 p.

  Research output: Contribution to journal › Article › peer-review
  44 Scopus citations

• Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

  Maiti, A., Cortes, J., Ferrajoli, A., Estrov, Z., Borthakur, G., Garcia-Manero, G., Jabbour, E., Ravandi, F., O’Brien, S. & Kantarjian, H., Sep 2 2017, In: Leukemia and Lymphoma. 58, 9, p. 2240-2242 3 p.

  Research output: Contribution to journal › Letter › peer-review
  4 Scopus citations

• Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

  Issa, G. C., Kantarjian, H. M., Xiao, L., Ning, J., Alvarado, Y., Borthakur, G., Daver, N., DiNardo, C. D., Jabbour, E., Bose, P., Jain, N., Kadia, T. M., Naqvi, K., Pemmaraju, N., Takahashi, K., Verstovsek, S., Andreeff, M., Kornblau, S. M., Estrov, Z., Ferrajoli, A. & 5 others, Garcia-Manero, G., Ohanian, M., Wierda, W. G., Ravandi, F. & Cortes, J. E., Nov 1 2020, In: Leukemia. 34, 11, p. 2914-2924 11 p.

  Research output: Contribution to journal › Article › peer-review
  5 Scopus citations

• Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

  Giles, F. J., Feldman, E. J., Roboz, G. J., Larson, R. A., Mamus, S. W., Cortes, J. E., Verstovsek, S., Faderl, S., Talpaz, M., Beran, M., Albitar, M., O'Brien, S. M. & Kantarjian, H. M., Dec 1 2003, In: Leukemia Research. 27, 12, p. 1091-1096 6 p.

  Research output: Contribution to journal › Article › peer-review
  20 Scopus citations

• Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

  Giles, F. J., Garcia-Manero, G., Cortes, J. E., Baker, S. D., Miller, C. B., O'Brien, S. M., Thomas, D. A., Andreeff, M., Bivins, C., Jolivet, J. & Kantarjian, H. M., Feb 1 2002, In: Journal of Clinical Oncology. 20, 3, p. 656-664 9 p.

  Research output: Contribution to journal › Article › peer-review
  71 Scopus citations

• Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

  Matulonis, U., Vergote, I., Backes, F., Martin, L. P., McMeekin, S., Birrer, M., Campana, F., Xu, Y., Egile, C. & Ghamande, S. A., Feb 1 2015, In: Gynecologic Oncology. 136, 2, p. 246-253 8 p.

  Research output: Contribution to journal › Article › peer-review
  75 Scopus citations

• Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

  Kesari, S., Schiff, D., Henson, J. W., Muzikansky, A., Gigas, D. C., Doherty, L., Batchelor, T. T., Longtine, J. A., Ligon, K. L., Weaver, S., Laforme, A., Ramakrishna, N., Black, P. M. L., Drappatz, J., Ciampa, A., Folkman, J., Kieran, M. & Wen, P. Y., Jun 2008, In: Neuro-Oncology. 10, 3, p. 300-308 9 p.

  Research output: Contribution to journal › Article › peer-review
  69 Scopus citations

• Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

  Thomas, D. A., Sarris, A. H., Cortes, J., Faderl, S., O'Brien, S., Giles, F. J., Garcia-Manero, G., Rodriguez, M. A., Cabanillas, F. & Kantarjian, H., Jan 1 2006, In: Cancer. 106, 1, p. 120-127 8 p.

  Research output: Contribution to journal › Article › peer-review
  64 Scopus citations

• Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

  Garg, R., Faderl, S., Garcia-Manero, G., Cortes, J., Koller, C., Huang, X., York, S., Pierce, S., Brandt, M., Beran, M., Borthakur, G., Kantarjian, H. & Ravandi, F., 2009, In: Leukemia. 23, 7, p. 1297-1302 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  38 Scopus citations

• Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

  Kurzrock, R., Albitar, M., Cortes, J. E., Estey, E. H., Faderl, S. H., Garcia-Manero, G., Thomas, D. A., Giles, F. J., Ryback, M. E., Thibault, A., De Porre, P. & Kantarjian, H. M., 2004, In: Journal of Clinical Oncology. 22, 7, p. 1287-1292 6 p.

  Research output: Contribution to journal › Article › peer-review
  144 Scopus citations

• Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

  Daver, N., Shastri, A., Kadia, T., Newberry, K., Pemmaraju, N., Jabbour, E., Zhou, L., Pierce, S., Cortes, J., Kantarjian, H. & Verstovsek, S., Sep 2014, In: Leukemia Research. 38, 9, p. 1126-1129 4 p.

  Research output: Contribution to journal › Article › peer-review
  27 Scopus citations

• Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

  Matulonis, U. A., Sharma, S., Ghamande, S. A., Gordon, M. S., Del Prete, S. A., Ray-Coquard, I., Kutarska, E., Liu, H., Fingert, H., Zhou, X., Danaee, H. & Schilder, R. J., Oct 2012, In: Gynecologic Oncology. 127, 1, p. 63-69 7 p.

  Research output: Contribution to journal › Article › peer-review
  116 Scopus citations

• Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

  Kadia, T. M., Kantarjian, H. M., Thomas, D. A., O'Brien, S., Estrov, Z., Ravandi, F., Jabbour, E., Pemmaraju, N., Daver, N., Wang, X., Jain, P., Pierce, S., Brandt, M., Garcia-Manero, G., Cortes, J. & Borthakur, G., Feb 1 2015, In: American Journal of Hematology. 90, 2, p. 120-124 5 p.

  Research output: Contribution to journal › Article › peer-review
  16 Scopus citations

• Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

  Issa, J. P. F., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S., Talpaz, M., Garcia-Manero, G. & Kantarjian, H. M., 2005, In: Journal of Clinical Oncology. 23, 17, p. 3948-3956 9 p.

  Research output: Contribution to journal › Article › peer-review
  263 Scopus citations

• Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

  Oki, Y., Kantarjian, H. M., Gharibyan, V., Jones, D., O'Brien, S., Verstovsek, S., Cortes, J., Morris, G. M., Garcia-Manero, G. & Issa, J. P. J., Mar 1 2007, In: Cancer. 109, 5, p. 899-906 8 p.

  Research output: Contribution to journal › Article › peer-review
  114 Scopus citations

• Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

  Vega-Ruiz, A., Cortes, J. E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., Kantarjian, H. M. & Verstovsek, S., Nov 2009, In: Leukemia Research. 33, 11, p. 1481-1484 4 p.

  Research output: Contribution to journal › Article › peer-review
  108 Scopus citations

• Phase II study of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

  Tsimberidou, A. M., O'Brien, S. M., Cortes, J. E., Faderl, S., Andreeff, M., Kantarjian, H. M., Keating, M. J. & Giles, F. J., 2002, In: Leukemia and Lymphoma. 43, 4, p. 767-772 6 p.

  Research output: Contribution to journal › Article › peer-review
  51 Scopus citations

• Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

  Wilson, W. H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S. M., Raffeld, M., Gutierrez, M., Chabner, B. A., Staudt, L., Jaffe, E. S. & Janik, J. E., 2008, In: Journal of Clinical Oncology. 26, 16, p. 2717-2724 8 p.

  Research output: Contribution to journal › Article › peer-review
  242 Scopus citations

• Phase II study of dasatinib in philadelphia chromosome - Negative acute and chronic myeloid diseases, including systemic mastocytosis

  Verstovsek, S., Tefferi, A., Cortes, J., O'Brien, S., Garcia-Manero, G., Pardanani, A., Akin, C., Faderl, S., Manshouri, T., Thomas, D. & Kantarjian, H., Jun 15 2008, In: Clinical Cancer Research. 14, 12, p. 3906-3915 10 p.

  Research output: Contribution to journal › Article › peer-review
  145 Scopus citations